PARAGON Trial

Trial A Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms.

Trial Acronym PARAGON

Protocol Number ANZGOG 0903

Key Question Does anastrozole, an aromatase inhibitor, improve outcomes in women with oestrogen receptor and/or progesterone receptor positive (ER/PR+ve) potentially hormone responsive recurrent or metastatic gynaecological cancers including selected patients with epithelial ovarian cancer, endometrial cancers, miscellaneous sarcomas and sex cord stromal tumours of the ovary?

Trial Design A multi-centre study with no control group.

ANZ Study Chair Prof Michael Friedlander

ANZ Coordinating Centre NHMRC Clinical Trials Centre - University of Sydney

Trial Coordinator John Stark

Trial Email paragon@ctc.usyd.edu.au

Tumour Stream Epithelial ovarian cancer; uterine or endometrial cancer

Intervention Registered patients are prescribed a 1mg Anastrozole (Arimidex) tablet daily (orally) until disease progression.

There is no control group so all patients are treated with the same type and amount of the study drug.

The study aims to establish the response rates, clinical benefit and quality of life as well as to identify predictors or response.

Eligibility The study will be open to all women with potentially hormone sensitive recurrent and metastatic gynaecological cancers. Patients who have:

• epithelial ovarian cancer,
• endometrial cancer,
• endometrial stromal sarcomas,
• granulosa cell/sex cord stromal tumours

Status Open to recruitment

Participating Sites Click through to ANZGOG website here.